Canopy Growth (CGC) Asset Writedowns and Impairment (2020 - 2023)
Canopy Growth's (CGC) quarterly Asset Writedowns and Impairment came in at $7.9 million in Q2 2023, down 99.42% year-on-year from $1.4 billion in Q2 2022, and down 97.14% quarter-over-quarter from $275.7 million in Q1 2023.
Canopy Growth (CGC) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends
Canopy Growth has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $7.9 million for Q2 2023.
- Asset Writedowns and Impairment for Q2 2023 came in at $7.9 million, down 99.42% year-over-year; the trailing twelve-month figure through Jun 2023 was $379.0 million (down 75.59% YoY), and the FY2023 annual result was $1.6 billion, up 526.97% from the prior year.
- Asset Writedowns and Impairment came in at $7.9 million for Q2 2023 at Canopy Growth, down from $275.7 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 billion in Q2 2022 to a low of -$809503.1 in Q3 2021.
- The 4-year median for Asset Writedowns and Impairment is $66.5 million (2021), against an average of $192.4 million.
- Across the five-year window, Asset Writedowns and Impairment surged 10927.04% in 2022 and tumbled 99.42% in 2023, its largest moves.
- Canopy Growth's Asset Writedowns and Impairment stood at $41.7 million in 2020, then sank by 38.12% to $25.8 million in 2021, then plunged by 69.77% to $7.8 million in 2022, then advanced by 0.88% to $7.9 million in 2023.
- The last three Asset Writedowns and Impairment figures came in at $7.9 million (Q2 2023), $275.7 million (Q1 2023), and $7.8 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 7.88 Mn |
| Jun 30, 2023 | 7.88 Mn |
| Mar 31, 2023 | 275.71 Mn |
| Mar 31, 2023 | 275.71 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Sep 30, 2022 | 87.65 Mn |
| Sep 30, 2022 | 87.65 Mn |
| Jun 30, 2022 | 1.35 Bn |
| Jun 30, 2022 | 1.35 Bn |
| Mar 31, 2022 | 173.45 Mn |
| Mar 31, 2022 | 173.45 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Sep 30, 2021 | -809,503.09 |
| Sep 30, 2021 | -809,503.09 |
| Jun 30, 2021 | 66.47 Mn |
| Jun 30, 2021 | 66.47 Mn |
| Mar 31, 2021 | 76.32 Mn |
| Mar 31, 2021 | 76.32 Mn |